Chongqing Cancer Institute Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2018
NCT03373058
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Chongqing Cancer Institute

Active Ingredients

Drugs in Phase 3 Trials (2)

carboplatin (paraplatin) (1 trial)

paclitaxel (taxol) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Ovarian Epithelial (Phase 3)

Fallopian Tube Neoplasms (Phase 3)

Ovarian Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 2